MX2007004276A - 1,5-naftiridin-azolidinonas que tienen actividad antiproliferativa de cdk-1. - Google Patents
1,5-naftiridin-azolidinonas que tienen actividad antiproliferativa de cdk-1.Info
- Publication number
- MX2007004276A MX2007004276A MX2007004276A MX2007004276A MX2007004276A MX 2007004276 A MX2007004276 A MX 2007004276A MX 2007004276 A MX2007004276 A MX 2007004276A MX 2007004276 A MX2007004276 A MX 2007004276A MX 2007004276 A MX2007004276 A MX 2007004276A
- Authority
- MX
- Mexico
- Prior art keywords
- azolidinones
- naphthyridine
- antiproliferative activity
- cdk1
- cdk1 antiproliferative
- Prior art date
Links
- IVOSKMBOJURGGQ-UHFFFAOYSA-N N1C(CCC1)=O.N1=CC=CC2=NC=CC=C12 Chemical class N1C(CCC1)=O.N1=CC=CC2=NC=CC=C12 IVOSKMBOJURGGQ-UHFFFAOYSA-N 0.000 title abstract 2
- 101150012716 CDK1 gene Proteins 0.000 title 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 title 1
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 abstract 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a las 1,5-naftiridin-azolidinonas de la formula (I) a los procesos para la fabricacion de dichos compuestos, asi como los medicamentos que los contienen. Estos compuestos soninhibidores de CDKl y muestran actividad antiproliferativa. Estos son por lo tanto Utiles como agentes anti-cancerosos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61880704P | 2004-10-14 | 2004-10-14 | |
| PCT/EP2005/010716 WO2006040052A1 (en) | 2004-10-14 | 2005-10-05 | 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007004276A true MX2007004276A (es) | 2007-05-16 |
Family
ID=36013291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007004276A MX2007004276A (es) | 2004-10-14 | 2005-10-05 | 1,5-naftiridin-azolidinonas que tienen actividad antiproliferativa de cdk-1. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7268231B2 (es) |
| EP (1) | EP1805174A1 (es) |
| JP (1) | JP2008516905A (es) |
| KR (2) | KR100875408B1 (es) |
| CN (1) | CN101039944B (es) |
| AU (1) | AU2005293835A1 (es) |
| BR (1) | BRPI0516488A (es) |
| CA (1) | CA2583192A1 (es) |
| MX (1) | MX2007004276A (es) |
| RU (1) | RU2405781C2 (es) |
| WO (1) | WO2006040052A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7304074B2 (en) * | 2005-04-05 | 2007-12-04 | Hoffmann-La Roche Inc. | Substituted 1,5-naphthyridine azolinones |
| TW200745066A (en) | 2005-09-16 | 2007-12-16 | Torrent Pharmaceuticals Ltd | Novel PTP1B inhibitors |
| FR2919608B1 (fr) * | 2007-08-01 | 2012-10-05 | Univ Rennes | Derives d'imidazolones,procede de preparation et applications biologiques |
| CN101555248B (zh) * | 2009-05-22 | 2011-06-22 | 北京欧凯纳斯科技有限公司 | 一种多取代1,5-萘啶化合物的制备方法 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| RU2521390C1 (ru) * | 2013-03-14 | 2014-06-27 | Общество с ограниченной ответственностью "Тиацен" | Производное роданина и средство для профилактики опухолевых заболеваний |
| JP6980385B2 (ja) | 2014-03-26 | 2021-12-15 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | Ｆｇｆｒ阻害剤とｉｇｆ１ｒ阻害剤の組合せ |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| MA55696A (fr) | 2014-03-26 | 2022-02-23 | Astex Therapeutics Ltd | Combinaisons |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| HRP20220012T1 (hr) | 2015-09-23 | 2022-04-01 | Janssen Pharmaceutica Nv | Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka |
| BR112018005637B1 (pt) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos |
| US11291861B2 (en) | 2019-03-08 | 2022-04-05 | Mevion Medical Systems, Inc. | Delivery of radiation by column and generating a treatment plan therefor |
| EP4143185B1 (en) * | 2020-04-30 | 2025-10-29 | Perha Pharmaceuticals | New imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4 |
| EP3904354A1 (en) * | 2020-04-30 | 2021-11-03 | Perha Pharmaceuticals | New imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4 |
| AR124154A1 (es) | 2020-11-27 | 2023-02-22 | Rhizen Pharmaceuticals Ag | Inhibidores de cdk |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| EP4173674A1 (en) | 2021-10-26 | 2023-05-03 | Perha Pharmaceuticals | Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1053668C (zh) * | 1994-06-14 | 2000-06-21 | 大日本制药株式会社 | 新型化合物及其制法和抗肿瘤剂 |
| MXPA05000453A (es) * | 2002-07-10 | 2005-03-23 | Applied Research Systems | Derivados de benceno fusionados a azolidinona-vinilo. |
| KR20050085115A (ko) | 2002-11-22 | 2005-08-29 | 스미스클라인 비참 코포레이션 | 신규 화합물 |
-
2005
- 2005-10-05 WO PCT/EP2005/010716 patent/WO2006040052A1/en not_active Ceased
- 2005-10-05 JP JP2007536046A patent/JP2008516905A/ja not_active Withdrawn
- 2005-10-05 EP EP05791894A patent/EP1805174A1/en not_active Withdrawn
- 2005-10-05 AU AU2005293835A patent/AU2005293835A1/en not_active Abandoned
- 2005-10-05 US US11/244,022 patent/US7268231B2/en not_active Expired - Fee Related
- 2005-10-05 RU RU2007117765/04A patent/RU2405781C2/ru not_active IP Right Cessation
- 2005-10-05 KR KR1020077008407A patent/KR100875408B1/ko not_active Expired - Fee Related
- 2005-10-05 MX MX2007004276A patent/MX2007004276A/es active IP Right Grant
- 2005-10-05 KR KR1020087018586A patent/KR20080075235A/ko not_active Ceased
- 2005-10-05 CA CA002583192A patent/CA2583192A1/en not_active Abandoned
- 2005-10-05 BR BRPI0516488-5A patent/BRPI0516488A/pt not_active IP Right Cessation
- 2005-10-05 CN CN2005800351115A patent/CN101039944B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080075235A (ko) | 2008-08-14 |
| RU2007117765A (ru) | 2008-11-20 |
| EP1805174A1 (en) | 2007-07-11 |
| AU2005293835A1 (en) | 2006-04-20 |
| US7268231B2 (en) | 2007-09-11 |
| CN101039944A (zh) | 2007-09-19 |
| CN101039944B (zh) | 2010-05-05 |
| CA2583192A1 (en) | 2006-04-20 |
| JP2008516905A (ja) | 2008-05-22 |
| RU2405781C2 (ru) | 2010-12-10 |
| KR20070053332A (ko) | 2007-05-23 |
| US20060084673A1 (en) | 2006-04-20 |
| WO2006040052A1 (en) | 2006-04-20 |
| KR100875408B1 (ko) | 2008-12-23 |
| BRPI0516488A (pt) | 2008-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007004276A (es) | 1,5-naftiridin-azolidinonas que tienen actividad antiproliferativa de cdk-1. | |
| NO20050525L (no) | Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer | |
| TW200800999A (en) | Novel compounds | |
| WO2004074244A3 (en) | Pyrimidine compounds | |
| MX2007003108A (es) | Compuestos imidazo-3-il-amina sustituidos y biciclicos. | |
| TW200801003A (en) | Novel compounds | |
| IL180722A0 (en) | Thienopyrimidine derivatives and pharmaceutical compositions containing the same | |
| AU2003228770A8 (en) | Substituted pyrazolopyrimidines | |
| TW200508214A (en) | Novel compounds | |
| TW200716606A (en) | Chemical compounds | |
| TW200800963A (en) | Chemical compounds | |
| SI1853602T1 (sl) | Kemične spojine | |
| PT1853588E (pt) | Compostos químicos | |
| ATE458485T1 (de) | Ubiquitin-ligase-hemmer und verwandte verfahren | |
| SE0302811D0 (sv) | Novel compounds | |
| MX2009004746A (es) | Derivados de 1,2,4-triazol como inhibidores del receptor sigma. | |
| MXPA05012025A (es) | Imidazo y tiazolopiridinas como inhibidores de cinasa jak3. | |
| TW200726753A (en) | 2,4-diamino-pyrimidines as aurora inhibitors | |
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| MX2007008924A (es) | Compuestos quimicos. | |
| TW200745084A (en) | Novel compounds | |
| TW200738659A (en) | Novel compounds | |
| NO20073631L (no) | Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel | |
| TW200635917A (en) | Novel compounds | |
| DE602006020295D1 (de) | Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |